PubMed Health⌕ Search

Biomedical subjects

Ata Kirilmaz

Publications and source records attributed to Ata Kirilmaz.

22 records · Page 2Linked to original sources
PubMed2003

Comparison of electrocardiographic repolarization patterns between hypogonad males and normal subjects.

BACKGROUND: There is a significant difference in repolarization on the surface ECG between men and women. The effect of testosterone on repolarization of myocardium may provide a basis for the physiological and pathophysiological importance of these distinctions between sexes. The purpose of this study is to compare the repolarization characteristics of surface ECG in patients with secondary hypogonadotropic hypogonadism to those of healthy men and women. METHODS: The study consisted of 45 consecutive patients with the diagnosis of secondary hypogonadotropic hypogonadism (study group) and age-, weight- and height-matched normal healthy men (n = 35) and women (n = 39) (control group). 12-lead ECG recordings were obtained and electronic calipers were used for measurements of ECG repolarization variables. ECG variables were compared with those of control groups. RESULTS: J point amplitude (0.12 +/- 0.07 vs 0.05 +/- 0.05 mV, respectively), T max (0.74 +/- 0.28 vs 0.60 +/- 0.27 mV, respectively), T wave area (81 +/- 36 vs 60 +/- 29 mVms, respectively) and T wave descending time (93 +/- 16 vs 85 +/- 15 ms, respectively) were significantly higher in healthy subjects than hypogonadal men. In comparison with those of healthy women, hypogonad males have higher J point (0.05 +/- 0.05 vs 0.02 +/- 0.02 mV), taller T wave (0.60 +/- 0.27 vs 0.34 +/- 0.13 mV), consequently less T wave area (60 +/- 29 vs 34 +/- 16 mVms), ascending (62 +/- 18 vs 53 +/- 11) and descending angle (67 +/- 17 vs 55 +/- 12). Corrected QT was not different among groups. CONCLUSIONS: Testosterone deprivation in hypogonadotropic hypogonadism attenuates J point, T wave peak, T wave area, and T wave descending time, but does not reach to the level of those in healthy women. Testosterone has no effect on QT interval in this group of age. Hormone replacement therapy of these patients will provide informative contribution.

Action Potentials↗
PubMed2003

Effect of homocysteine-lowering therapy on vascular endothelial function and exercise performance in coronary patients with hyperhomocysteinaemia.

OBJECTIVE: This study was performed to determine the effect of homocysteine-lowering therapy (HLT) on endothelium-dependent vasodilation (EDD) and exercise performance in patients with coronary artery disease. METHODS AND RESULTS: Among the patients who were on the waiting list for coronary intervention, 26 male patients (plasma homocysteine (Hcy) levels > 15 micromol/l) who had a focal stenosis of at least 70% in the left anterior descending artery were included in the study. The patients were matched to receive HLT (n = 15; 0.4 mg of folic acid, 2 mg vitamin B6 and 6 microg of vitamin B12) or placebo (n = 11) until the coronary intervention was performed (mean 3.8 +/- 0.9 weeks). Brachial artery vasomotion test and treadmill stress testing were performed at baseline and 4 weeks after HLT before the time of coronary intervention in each patient. Hcy levels were found to be decreased significantly after HLT compared to baseline (23.4 +/- 6 vs. 11.3 +/- 4 micromol/l; p < 0.001) whereas placebo had no effect. HLT but not placebo produced a marked improvement in EDD, from 3.9 +/- 1.1% to 9.4 +/- 2.3% (p < 0.0001). Endothelium-independent nitroglycerin-induced dilation was similar in the HLT and placebo groups compared with the baseline. In the exercise testing, HLT resulted in a significant improvement in exercise duration and reduction in the amount of maximal ST-segment depression, (from 6.5 +/- 2 to 6.9 +/- 2 min, p = 0.02 and from 1.2 +/- 0.7 to 0.8 +/- 0.5 mm, p = 0.01, respectively) whereas placebo did not. CONCLUSION: Lowering Hcy levels improves EDD and exercise performance while reducing the exercise-induced myocardial ischaemia in patients with coronary heart disease and hyperhomocysteinaemia.

Aged↗
PubMedDate not supplied

Tricuspid insufficiency does not increase early after permanent implantation of pacemaker leads.

BACKGROUND: Interference between pacemaker (PM) lead and tricuspid apparatus may cause tricuspid regurgitation (TR). However, data regarding TR in patients with implanted PM are controversial. Our aim is to find out the degree of TR in a group of patients before and following PM implantation in a prospective manner. METHODS: The study group consisted of the patients referred for implantation of permanent PM or implantable cardioverter defibrillator (ICD). All patients underwent two-dimensional and Doppler echocardiographic evaluation before and after device implantation. The severity of TR was qualitatively classified into four groups as normal or trivial, mild, moderate, or severe. All studies were reviewed for accuracy by a second independent interpreter. RESULTS: Sixty-one patients (mean age 53 +/- 8 years, 44 male) referred for PM (n = 55) or ICD (n = 6) implantation consisted of the study population. Echocardiographic degree of TR was mild in 21 (70%), moderate in 7 (23%) and severe in 2 (7%) patients before PM implantation. Following device implantation, mild TR was noted in 23 (76%), moderate in 10 (33%), and severe in 2 (6%) cases. After the procedure, the TR severity was increased from normal/trivial to mild in 5 (16%) cases and from mild to moderate in 3 (10%). There was no worsening of the severity of TR in patients with moderate regurgitation following device implantation. The severity of TR did not change at a mean follow-up of 6 +/- 3 months. CONCLUSIONS: New or worsening TR is relatively rare after PM implantation. It is not associated with an acute worsening or clinical deterioration. But echocardiographic follow-up is recommended to monitor other complications in chronic phase.

Cardiomyopathy, Dilated↗